Innovation in India? Symmetrix launches phase II of targeted thrombolytic
HONG KONG – Regulators in India have approved phase II trials for the protein drug that targets blood clots and could help treat heart attack patients with fewer risks and side effects than existing treatments. It may be the first biopharmaceutical compound fully developed in the country.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST